David Wild

Sheer horror. This is not what resistance looks like

John Spencer @SpencerGuard

I just watched the roughly 45-minute footage of October 7th at a private screening in NYC. Here are my immediate thoughts minutes after watching it. 🧵

RT @harari_yuval: During times of conflict and suffering, we can only hope that outsiders who are not immediately affected will nurture see…

Over 10 data analyses at #DDW2023 strengthen the evidence base for use of AbbVie's Rinvoq In Crohn's https://t.co/Morffcx9HU @INVIVOnow

RT @benevolent_ai: “In a crowded AI-driven drug development sector, BenevolentAI stands out with its broad pipeline of drug candidates, dee…

At #BiotechShowcase, Ovid Therapeutics CEO Jeremy Levin says the Inflation Reduction Act’s passage was a failure of the industry to educate voters and legislators. Good news is that framework for implementation is still up for negotiation.

RT @PinkSheetDenise: Look for @jessicaemerrill @scripmandy and @davidwild77 reporting from JPM health care conf next week (and at the best…

With the ⁦@US_FDA⁩ approval of #Rebyota, the era of standardized #microbiome treatments has begun. A look at the microbiome pipeline for recurrent C. difficile shows treatments becoming smarter and possibly safer. ⁦@INVIVOnow⁩ https://t.co/7q2WD215ns

Competition is fierce when it comes to finding diverse talent in biopharma! I spoke with folks at @GileadSciences, @sanofi and @82VentureStudio about their strategies for attracting and retaining employees from traditionally underrepresented groups. https://t.co/H5cB17pPUa

My first go as a podcast host! I enjoyed the process and this interview with Petra Jantzer of Accenture

In Vivo, Citeline Commercial @INVIVOnow

Accenture's Petra Jantzer On Changing M&A Strategies https://t.co/X8iM6GUUcd

It's a rare thing to see pharma competitors collaborate. In this article for @INVIVOnow, I report on one such collaboration, to improve the power of AI in drug discovery.

Owkin @OwkinScience

“The goal is for each participant to benefit from a larger pool of data than their own, resulting in increased machine learning performance, while respecting data ownership and privacy.” Read @m_galtier on the implications of @MELLODDY_IMI in @INVIVOnow. https://t.co/awPYp0TEbL

Black Death may have influenced evolution of genes involved in immune responses, possibly increasing risk of #Crohns disease https://t.co/TiXB1TDwtN via @statnews

RT @EmilyLeproust: We are always aiming to be the value add for our customers- to support their projects. Thanks @davidwild77 and @INVIVOno…

RT @Pharnext: Great article by @davidwild77 in @InVivo on the challenges of recruiting patients for rare disease trials. Read it to learn h…

Fake medicines kill hundreds of thousands each year. I looked into what's being done to tackle the problem. Patient education is key!! #fakemeds #patientsafety @INVIVOnow https://t.co/DlIbH5uQgz

Whole foods for the win #microbiome

John Damianos, M.D. @john_damianosMD

Both the Mediterranean #diet and Green-Med diet ▶️ favorable changes in the #gut microbiota, as well as improved cardiometabolic parameters including body weight and blood pressure, largely mediated by #microbiome changes. 🥦🍓🧄🥑 #MedTwitter #nutrition https://t.co/oSjuyQ6UE7

Open-Label #Placebo Improves Symptoms in #Pediatric #IBS https://t.co/h3naE1H793

Placebos have been around for ages and are safe and effective in a pretty impressive amount of cases. Hopefully MDs will find the right place for them in their medicine cabinet. https://t.co/h3naE1H793